Home > Insider Trading > Filing (0001599901-24-000188)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1599901	Avidity Biosciences Inc.	RNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1383731	F Michael Maclean	C/O Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego CA 92121	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2024-11-06	27,262	$46.22	94,093	No	4	S	Direct
Common Stock	Acquisiton	2024-11-06	65,182	$8.82	159,275	No	4	M	Direct
Common Stock	Disposition	2024-11-06	65,182	$45.33	94,093	No	4	S	Direct
Common Stock	Acquisiton	2024-11-06	13,875	$6.57	107,968	No	4	M	Direct
Common Stock	Disposition	2024-11-06	13,875	$45.33	94,093	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-11-06	65,182	$0.00	65,182	$8.82
Common Stock	Stock Option (Right to Buy)	Disposition	2024-11-06	13,875	$0.00	13,875	$6.57

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2030-05-14	No	4	M	Direct
60,125		2033-09-10	No	4	M	Direct

Footnotes

The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on July 8, 2024.
This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.86 to $48.01. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $48.01. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All shares subject to this option have fully vested as of the date of this report.
1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of September 11, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the option shall be fully vested on the fourth anniversary of the Vesting Commencement Date.